中欣氟材(002915.SZ):監事何黎媛完成減持 累計減持16.25萬股
格隆匯6月8日丨中欣氟材(002915.SZ)公佈,公司於2020年2月21日披露,公司監事何黎媛持有公司股份65萬股,佔公司總股本的0.48%,在減持計劃披露之日起15個交易日後的6個月內,計劃通過包括但不限於二級市場集中競價、大宗交易方式、協議轉讓方式減持所持公司股份數量不超過16.25萬股,即不超過公司總股本的0.12%。
2020年6月8日,公司董事會收到何黎媛出具的《股份減持計劃實施完成告知函》,何黎媛在減持計劃實施期間累計減持16.25萬股,佔公司總股本的0.12%,其減持計劃已實施完畢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.